Présentation de l'entreprise
Scholar Rock Holding Corporation operates as a biopharmaceutical entity dedicated to advancing the lives of pediatric and adult patients suffering from spinal muscular atrophy (SMA) alongside other rare, severe, and debilitating neuromuscular diseases. The company functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high capital expenditure requirements and the development of novel therapies based on molecular mechanisms of growth factor activity. As of the latest reported data, the organization maintains a substantial market capitalization of $5.74 billion and employs a workforce of 289 individuals. These financial metrics indicate that the market assigns a significant valuation premium to the company's pipeline of neuromuscular therapeutics, suggesting strong investor confidence in the potential clinical and commercial success of its proprietary research despite the current lack of reported revenue figures.
Santé financière
The financial statements for Scholar Rock Holding Corporation show a Net Income of $-377,939,008 and an EBITDA of $-382,987,008, while the Revenue (TTM) is reported as N/A. The substantial gap between the reported net income and EBITDA, alongside the absence of revenue, reveals a cost structure typical of early-stage biotechnology firms where operational expenses are heavily weighted toward research and development rather than commercial sales. The company reports a Free Cash Flow of $-162,622,256, which indicates that current cash outflows for operations and capital expenditures exceed cash generated, reflecting a financial phase focused on asset accumulation and clinical trial progression rather than cash generation. All three margin metrics—the Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that signifies the company has not yet generated commercial revenue to establish positive operating leverage or profitability. Regarding liquidity and leverage, the company holds $367.56 million in cash against $108.92 million in debt, resulting in a Debt to Equity ratio of 44.37. While the absolute debt level is manageable relative to cash reserves, the high debt-to-equity ratio suggests a leveraged balance sheet structure common in capital-intensive biotech sectors. The Current Ratio stands at 6.95, indicating that the company possesses more than six times the current assets necessary to cover its short-term liabilities, thereby demonstrating robust short-term liquidity positions. Finally, the Return on Equity is -123.1% and the Return on Assets is -54.7%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate negative returns due to the heavy investment required in its pre-revenue development stage.
Évaluation de la valorisation
The valuation metrics for Scholar Rock Holding Corporation present a Trailing P/E Ratio (TTM) as N/A and a Forward P/E of -23.30, implying that the market prices the stock based on anticipated future earnings rather than historical performance, as negative earnings prevent the calculation of a standard trailing multiple. The Price to Book ratio is recorded at 22.09, indicating that the market values the company at more than twenty-two times its net asset value, which reflects a significant premium assigned to the intellectual property and pipeline potential over tangible book value. Alternative valuation measures such as the Price to Sales ratio are listed as N/A due to the lack of revenue, while the EV/EBITDA stands at -14.32, further confirming that traditional earnings-based valuation models are not applicable at this stage of the business lifecycle. The stock's trading range over the past year spans from a 52-Week Low of $22.71 to a 52-Week High of $51.62, providing a reference band for price volatility and historical performance extremes. The Beta value is 0.69, which suggests that the stock's price volatility is significantly lower than that of the broader market, indicating that the security may be less sensitive to general market fluctuations compared to larger-cap equities.
Growth & Income
The reported Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning that historical growth rates cannot be calculated due to the absence of prior period revenue data required for comparison. For a non-dividend payer, the company does not distribute cash to shareholders, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This financial strategy implies that the organization retains all available earnings and cash reserves to reinvest directly into research, development, and clinical trials to accelerate the growth of its neuromuscular disease pipeline. Consequently, the overall growth and income profile of Scholar Rock Holding Corporation is defined by a focus on capital deployment for product development rather than the generation of current income or dividend distributions for investors.